Fig. 3: PEG-A1 treatment ameliorates the OIR-induced inflammatory response and reduces VEGF while increasing FGF2. | Cell Death & Disease

Fig. 3: PEG-A1 treatment ameliorates the OIR-induced inflammatory response and reduces VEGF while increasing FGF2.

From: Targeting proliferative retinopathy: Arginase 1 limits vitreoretinal neovascularization and promotes angiogenic repair

Fig. 3

A–H Analysis of mRNA levels showed upregulation of TNF, IL-6, MCP1, and VEGF in OIR retinas at P13. PEG-A1 treatment significantly reduced TNF and VEGF and showed a trend towards a reduction in IL-6 and MCP1. PEG-A1 treatment also showed a trend towards increasing the neurotrophic factor CNTF at P13. Analysis at P17 showed upregulation of iNOS mRNA after OIR, which was significantly reduced with PEG-A1 treatment. Furthermore, PEG-A1 treatment increased the mRNA levels of A1 and FGF2 at P17. I–K Western blotting of retina lysates at P17 showed upregulation of low molecular weight (LMW) FGF2 (18 kDa band) with PEG-A1 treatment as compared to vehicle with a similar increase in the high molecular weight (HMW) FGF2 but the later did not reach statistical significance. L, M Immunolabeling of retina flatmounts at P17 showed co-localization of FGF2 with F4/80 (microglia/macrophage marker) and lectin (blood vessel marker) (arrows). Image quantification showed upregulation of FGF2/F4/80 double-positive cells with PEG-A1 treatment. Scale bar = 20 µm. N, O Immunolabeling of retina flatmounts at P17 showed co-localization of the M2 macrophage marker CD206 with the M1 marker CD16/32. Image quantification showed upregulation of CD16/32 / CD206 double-positive cells with PEG-A1 treatment. Scale bar = 20 µm.

Back to article page